



General description

INN	Vinblastine
ATC codes	L01CA01
Medicine type	Chemical agent
EML status history	<p>First added in 1984 (TRS 722) for <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b></p> <p>Added in 2015 (TRS 994) for <b>Hodgkin lymphoma</b></p> <p>Added in 2015 (TRS 994) for <b>Kaposi sarcoma of unspecified primary site</b></p> <p>Added in 2015 (TRS 994) for <b>Germ cell tumour of testis</b></p> <p>Added in 2015 (TRS 994) for <b>Other specified malignant neoplasms of the ovary</b></p> <p>Removed in 2015 (TRS 994) for <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b></p> <p>Added in 2021 (TRS 1035) for <b>Other specified gliomas of brain</b></p> <p>Added in 2023 (TRS 1049) for <b>Anaplastic large cell lymphoma, ALK-positive</b></p> <p>Added in 2023 (TRS 1049) for <b>Anaplastic large cell lymphoma, ALK-negative</b></p> <p>Added in 2023 (TRS 1049) for <b>Langerhans cell histiocytosis</b></p>
Wikipedia	<a href="#">Vinblastine</a> 
DrugBank	<a href="#">Vinblastine</a> 

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)  
 Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

- Hodgkin lymphoma
- Kaposi sarcoma of unspecified primary site
- Germ cell tumour of testis
- Other specified malignant neoplasms of the ovary
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Other specified gliomas of brain
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Langerhans cell histiocytosis



